Rifapentine indications and usage: Difference between revisions
No edit summary |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 14: | Line 14: | ||
Rifapentine should not be used as monotherapy in either the initial or the continuation phases of antituberculous treatment.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PRIFTIN (RIFAPENTINE) TABLET, FILM COATED [SANOFI-AVENTIS U.S. LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f768e337-a948-420a-9fbe-9be359c7a170 | publisher = | date = | accessdate = }}</ref> | Rifapentine should not be used as monotherapy in either the initial or the continuation phases of antituberculous treatment.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PRIFTIN (RIFAPENTINE) TABLET, FILM COATED [SANOFI-AVENTIS U.S. LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f768e337-a948-420a-9fbe-9be359c7a170 | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Latest revision as of 16:35, 6 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Indications And Usage
Rifapentine is indicated for the treatment of pulmonary tuberculosis caused by Mycobacterium tuberculosis. Rifapentine must always be used in combination with one or more antituberculosis drugs to which the isolate is susceptible depending on the phase of treatment [see Dosage and Administration and Clinical Studies .
Limitations of Use
Rifapentine should not be used as a once weekly Continuation Phase regimen in combination with isoniazid in HIV seropositive patients with pulmonary tuberculosis because of a higher rate of failure and/or relapse documented with the presence of rifampin-resistant organisms [see Warnings and Precautions and Clinical Studies ].
Rifapentine has not been studied as part of the Initial Phase treatment regimen in HIV seropositive patients with pulmonary tuberculosis.
Rifapentine should not be used as monotherapy in either the initial or the continuation phases of antituberculous treatment.[1]
References
Adapted from the FDA Package Insert.